Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female, 18-65 years of age at the time of enrollment;~* Ability to understand and provide written informed consent;~* Candidate for primary renal allograft from either living or deceased donor;~* No known contraindications to study therapy using NULOJIX® (belatacept);~* Female participants of childbearing potential must have a negative pregnancy test upon study entry;~* Participants with reproductive potential must agree to use an appropriate method(s) of birth control as outlined in the CellCept® , Myfortic® or generic package labeling during participation in the study and for 4 months following completion of the study;~* No donor specific antibodies prior to transplant that are considered to be of clinical significance by the site investigator;~* Negative crossmatch or Panel Reactive Antibodies (PRA) of 0% on historic and current sera, as determined by each participating study center;~* A documented negative tuberculosis (TB) test within the 6 months prior to transplant. If documentation is not present at the time of transplantation, and the subject does not have any risk factors for TB, a TB-specific interferon gamma release assay (IGRA) may be performed.~Exclusion Criteria:~* Need for multi-organ transplant;~* Recipient of previous organ transplant;~* Epstein-Barr Virus (EBV) seronegative (or unknown) recipients;~* Active infection including hepatitis B, hepatitis C, or human Immunodeficiency Virus (HIV);~* Individuals who have required treatment with prednisone or other immunosuppressive drugs within 1 year prior to transplant;~* Individuals undergoing transplant using organs from extended criteria donor (ECD) or donation after cardiac death (DCD) donors;~* Histocompatibility antigen (HLA) identical living donors;~* Individuals at significant risk of early recurrence of the primary renal disease including focal segmental glomerulosclerosis (FSGS) and membranoproliferative glomerulonephritis (MPGN) type 2 or any other disease that in the opinion of the investigator is at increased likelihood of recurrence and which may result in rapid decline in renal function;~* Known history of thrombotic events or risk factors, including any of the following:~  * Factor V Leiden, elevated homocysteine, positive lupus anticoagulant, elevated anticardiolipin antibody, heparin-induced thrombocytopenia,~ * A family history of a heritable thrombotic condition,~ * Recurrent deep vein thrombosis (DVT) or pulmonary emboli (PE),~ * Unexplained stillborn infant or recurrent spontaneous abortion or other congenital or acquired thrombotic disorder.~At the discretion of the investigator, a history of thrombosis of a dialysis access graft, fistula, or indwelling catheter/device may not be considered an exclusion criterion.~* Any condition that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements;~* Use of investigational drugs within 4 weeks of enrollment;~* Known hypersensitivity to mycophenolate mofetil (MMF)or any of the drug's components;~* Administration of live attenuated vaccine(s) within 8 weeks of enrollment;~* Blood type A2 and A2B donors into blood type B recipients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Thymoglobulin®+tacrolimus+MMF (Type: ACTIVE_COMPARATOR): Induction with Thymoglobulin®, methylprednisolone, and maintenance immunosuppression with tacrolimus and mycophenolate mofetil (MMF)
- Thymoglobulin®+belatacept+MMF (Type: EXPERIMENTAL): Induction with Thymoglobulin®, methylprednisolone, and maintenance with belatacept and mycophenolate mofetil (MMF)
- Basiliximab+20 weeks of tacrolimus+MMF + belatacept (Type: EXPERIMENTAL): Induction basiliximab and methylprednisolone, administration of NULOJIX® (belatacept) 24 hours post reperfusion (+/-12 hrs); maintenance immunosuppression with 1. )20 week course of Prograf® (tacrolimus) or equivalent 2.) CellCept® (mycophenolate mofetil- MMF), or Myfortic® (mycophenolate sodium), or equivalent.~Subjects participating in this arm may have tacrolimus reinstated, at a dose to be determined by the site investigator, if any of the following events occur: 1 - An acute rejection episode 2- Request of the subject or site Investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility